Tomasz Wróbel

4.6k total citations · 1 hit paper
198 papers, 1.9k citations indexed

About

Tomasz Wróbel is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Tomasz Wróbel has authored 198 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Genetics, 66 papers in Oncology and 62 papers in Pathology and Forensic Medicine. Recurrent topics in Tomasz Wróbel's work include Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers). Tomasz Wróbel is often cited by papers focused on Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers). Tomasz Wróbel collaborates with scholars based in Poland, United States and France. Tomasz Wróbel's co-authors include Justyna Rybka, Kazimierz Kuliczkowski, Grzegorz Mazur, Katarzyna Wicherska‐Pawłowska, Katarzyna Bogunia‐Kubik, Bożena Jaźwiec, Monika Biernat, Aleksandra Butrym, Andrzej Lange and Rafał Poręba and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tomasz Wróbel

171 papers receiving 1.9k citations

Hit Papers

Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), an... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases
    2021 227 citations Katarzyna Wicherska‐Pawłowska, Tomasz Wróbel et al. International Journal of Molecular Sciences profile →

Peers

Tomasz Wróbel
E. Thiel Germany
Belinda Pinto Simões Brazil
Alessandra Romano Italy
Kazuyuki Matsuda Japan
Shigeto Tohma Japan
Federico Perosa Italy
Hiroaki Goto Japan
Armin Gerbitz Canada
Steven H. Kroft United States
Peter H. Sayre United States
E. Thiel Germany
Tomasz Wróbel
Citations per year, relative to Tomasz Wróbel Tomasz Wróbel (= 1×) peers E. Thiel

Countries citing papers authored by Tomasz Wróbel

Since Specialization
Citations

This map shows the geographic impact of Tomasz Wróbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomasz Wróbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomasz Wróbel more than expected).

Fields of papers citing papers by Tomasz Wróbel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomasz Wróbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomasz Wróbel. The network helps show where Tomasz Wróbel may publish in the future.

Co-authorship network of co-authors of Tomasz Wróbel

This figure shows the co-authorship network connecting the top 25 collaborators of Tomasz Wróbel. A scholar is included among the top collaborators of Tomasz Wróbel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomasz Wróbel. Tomasz Wróbel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gąsior‐Głogowska, Marlena, et al.. (2025). Effects of DNA Methylation Inhibitors on Molecular and Structural Changes in Chromatin Organization in Leukemia Cells. Molecular and Cellular Biology. 46(1). 1–20.
2.
3.
Kiełbus, Michał, Joanna Zaleska, Ewa Wawrzyniak, et al.. (2024). Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia. Oncology Letters. 28(5). 552–552. 4 indexed citations
4.
Puła, Bartosz, Elżbieta Iskierka‐Jazdzewska, Krzysztof Jamroziak, et al.. (2024). Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment. Acta Haematologica Polonica. 55(3). 130–136. 2 indexed citations
5.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations
6.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7008–7008. 7 indexed citations
7.
8.
Wróbel, Tomasz, et al.. (2023). Bispecific antibodies in the treatment of follicular lymphoma. 14(0). 80–86.
9.
Wróbel, Tomasz, et al.. (2023). The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. International Journal of Molecular Sciences. 24(5). 4708–4708. 6 indexed citations
10.
Wicherska‐Pawłowska, Katarzyna, Katarzyna Bogunia‐Kubik, Piotr Łacina, et al.. (2022). Polymorphisms in the Genes Coding for TLRs, NLRs and RLRs Are Associated with Clinical Parameters of Patients with Acute Myeloid Leukemia. International Journal of Molecular Sciences. 23(17). 9593–9593. 3 indexed citations
11.
Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128. 20 indexed citations
12.
Kalicińska, Elżbieta, Barbara Adamik, Danuta Nowicka‐Suszko, et al.. (2021). Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. Cells. 10(6). 1293–1293. 20 indexed citations
13.
Kalicińska, Elżbieta, Monika Biernat, Justyna Rybka, et al.. (2021). Endothelial Activation and Stress Index (EASIX) as an Early Predictor for Mortality and Overall Survival in Hematological and Non-Hematological Patients with COVID-19: Multicenter Cohort Study. Journal of Clinical Medicine. 10(19). 4373–4373. 21 indexed citations
14.
Kalicińska, Elżbieta, et al.. (2020). Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study. Translational Oncology. 14(1). 100943–100943. 12 indexed citations
15.
16.
Mazur, Grzegorz, Emilia Jaskuła, Ilona Kryczek, et al.. (2011). Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin’s lymphoma. SHILAP Revista de lepidopterología. 2 indexed citations
17.
Wróbel, Tomasz, et al.. (2010). Mechanisms of Resistance to Cancer Chemotherapy. Advances in Clinical and Experimental Medicine. 19(1). 5–12. 3 indexed citations
18.
Jurczak, Wojciech, Alicja Hubalewska‐Dydejczyk, Agnieszka Giza, et al.. (2007). Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience.. PubMed. 10(2). 91–7. 2 indexed citations
19.
Mazur, Grzegorz, Agnieszka Hałoń, Tomasz Wróbel, & Kazimierz Kuliczkowski. (2004). Macrophage/histiocytic antigen CD68 expression in neoplastic and reactive lymph nodes.. PubMed. 49 Suppl 1. 73–5. 5 indexed citations
20.
Mazur, Grzegorz, Tomasz Wróbel, Maria Podolak‐Dawidziak, et al.. (2004). [Anagrelide in the treatment of thrombocythemia essential (ET)].. PubMed. 112(6). 1445–50. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Thiel Breakdown of academic impact, for papers by Belinda Pinto Simões Breakdown of academic impact, for papers by Alessandra Romano Breakdown of academic impact, for papers by Kazuyuki Matsuda Breakdown of academic impact, for papers by Shigeto Tohma Breakdown of academic impact, for papers by Federico Perosa Breakdown of academic impact, for papers by Hiroaki Goto Breakdown of academic impact, for papers by Armin Gerbitz Breakdown of academic impact, for papers by Steven H. Kroft Breakdown of academic impact, for papers by Peter H. Sayre
Rankless by CCL
2026